9 Meters Biopharma, EBRIS Foundation Team Up For Larazotide Trial For COVID-19-Associated Complication In Children

9 Meters Biopharma Inc NMTR has collaborated with the European Biomedical Research Institute of Salerno, Italy (EBRIS) to study larazotide for multisystem inflammatory syndrome in children (MIS-C).
Larazotide is a novel first-in-class tight junction regulator that the Company currently has in Phase 3 trial for adults with celiac disease.
MIS-C is a severe and rare complication of COVID-19 with symptoms potentially including persistent fever, gastrointestinal symptoms, myocardial dysfunction, and cardiogenic shock with ventricular dysfunction in the setting of multisystem inflammation.
EBRIS plans to initiate a Phase 2a study in MIS-C in Q4 2021.
Under the terms of the collaboration agreement, 9 Meters will supply larazotide, and EBRIS will be responsible for conducting the Phase 2a trial inclusive of all associated clinical costs.
Data readout is expected in 2022. Other financial terms of the transaction are undisclosed.
Price Action: NMTR shares are up 0.48% at $1.04 during the market session on the last check Monday.